CompanyAccess Bio, Inc.
United States of America
Access Bio is dedicated to the prevention and early diagnosis of infectious diseases through research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. Particularly, early and accurate diagnosis is a key to effective treatment of patients. Their core in vitro diagnostic technology includes immunochemical, biochemical and molecular products. Access Bio strives to establish a foundation for wellbeing of all people.
Private/Public:
public
Phone:+1-732-873-4040
Address:65 Clyde Rd. Suite A, Somerset, NJ 08873, United States of America
Product Groups
For Services/Products
Diagnostics
Diagnostic assay development/manufacturing
Diagnostic Product Offerings
- Specific Diagnostic Kit (IVD) Product Offerings
- Infectious Disease Test Kits
- POC Diagnostic Test Kits
Medical and Delivery Devices
Diagnostic Equipment Offerings
United States of America
- (30.May.2022) Access Bio Gets Stake in ECG Analysis Solution Bio Venture
- (27.Jan.2022) Atomo Receives Approval for Its COVID-19 Antigen Test in NZ
- (14.Jan.2022) Vivera Pharmaceuticals Issues Statement Regarding LuSys Laboratories COVID-19 Tests
- (05.Oct.2021) Atomo and Access Bio Renegotiate Supply Agreements
- (23.Sep.2021) Access Bio, PharmGen Science to Develop Biosimilar Covid-19 Vaccine
- (04.Aug.2021) Thermo Fisher Scientific, Access Bio, LumiraDx Get FDA EUAs for SARS-CoV-2 Tests
- (30.Jun.2021) Vivera Pharmaceuticals Partners With Areum Bio LLC and Access Bio, Inc. To Expand the National Distribution of Emergency Use Authorized COVID-19 Rapid Tests
- (28.Jun.2021) Access Bio Receives FDA Clearance for COVID-19 Antibody Test